Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control
Study Details
Study Description
Brief Summary
Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The health status of normal individuals and patients with various diseases is commonly monitored using the complete blood count (CBC). In patients with T2DM, the CBC can be used as a follow-up test, which will help in reducing complications associated with the disease. Some CBC parameters have also been used as prognostic markers for T2DM. One of these markers is the red cell distribution width (RDW), which measures the variability in the sizes of red blood cells (RBCs) and is considered an indicator of their heterogeneity. The evidence associating RDW with a higher risk of mortality has been expanding since the initial report of its prognostic utility in heart failure patients. Multiple studies have shown that elevated RDW values are associated with many human diseases, such as cancer, cardiovascular disease, and diabetes, and are also associated with disease activity or complications of diseases. The RDW can be used diagnostically in patients with T2DM and other illnesses, as patients with T2DM frequently show alterations in various hematological properties, including changes in the structure, metabolism, and function of blood cells. These alterations can be caused by different factors, such as excessive levels of reactive oxygen species (ROS), leading eventually to oxidative stress and the dysfunction of RBCs.
The relationship between RDW and T2DM has been studied for several years, and there are no consistent results.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 1 Prediabetics |
Diagnostic Test: Glycated hemoglobin (HbA1C)
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
Diagnostic Test: RDW
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
Diagnostic Test: Lipid profile
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
|
| 2 Diabetics |
Diagnostic Test: Glycated hemoglobin (HbA1C)
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
Diagnostic Test: RDW
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
Diagnostic Test: Lipid profile
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
|
| 3 Healthy control |
Diagnostic Test: Glycated hemoglobin (HbA1C)
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
Diagnostic Test: RDW
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
Diagnostic Test: Lipid profile
Blood test will be done at time of recruitment (for 3 groups) , after 3 months and after 6 months (for group 1 and 2)
|
Outcome Measures
Primary Outcome Measures
- To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control. ["At time of inclusion in the study", "3 months", "6 months"]
Secondary Outcome Measures
- To determine if changes in RDW levels correlate with the presence of other comorbidities and complications. [once]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients diagnosed to have type 2 diabetes or prediabetics
Exclusion Criteria:
-
Patients diagnosed with type 1 diabetes.
-
Patients are diagnosed with secondary diabetes.
-
Patients with anemia
-
Patients with liver disease, or any other significant comorbidities that may affect RDW or HbA1C levels
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- New Valley University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Arkew M, Yemane T, Mengistu Y, Gemechu K, Tesfaye G. Hematological parameters of type 2 diabetic adult patients at Debre Berhan Referral Hospital, Northeast Ethiopia: A comparative cross-sectional study. PLoS One. 2021 Jun 14;16(6):e0253286. doi: 10.1371/journal.pone.0253286. eCollection 2021.
- Bhutto AR, Abbasi A, Abro AH. Correlation of Hemoglobin A1c with Red Cell Width Distribution and Other Parameters of Red Blood Cells in Type II Diabetes Mellitus. Cureus. 2019 Aug 30;11(8):e5533. doi: 10.7759/cureus.5533.
- Nah EH, Cho S, Park H, Kim S, Cho HI. Associations of complete blood count parameters with pancreatic beta-cell function and insulin resistance in prediabetes and type 2 diabetes mellitus. J Clin Lab Anal. 2022 Jun;36(6):e24454. doi: 10.1002/jcla.24454. Epub 2022 May 13.
- Ooi TC, Mat Ludin AF, Loke SC, Fiatarone Singh MA, Wong TW, Vytialingam N, Anthony Abdullah MMJ, Ng OC, Bahar N, Zainudin N, Lew LC. A 16-Week Home-Based Progressive Resistance Tube Training Among Older Adults With Type-2 Diabetes Mellitus: Effect on Glycemic Control. Gerontol Geriatr Med. 2021 Aug 12;7:23337214211038789. doi: 10.1177/23337214211038789. eCollection 2021 Jan-Dec.
- Valtierra-Alvarado MA, Castaneda Delgado JE, Ramirez-Talavera SI, Lugo-Villarino G, Duenas-Arteaga F, Lugo-Sanchez A, Adame-Villalpando MS, Rivas-Santiago B, Enciso-Moreno J, Serrano CJ. Type 2 diabetes mellitus metabolic control correlates with the phenotype of human monocytes and monocyte-derived macrophages. J Diabetes Complications. 2020 Nov;34(11):107708. doi: 10.1016/j.jdiacomp.2020.107708. Epub 2020 Aug 13.
- T2DMRDW